Heparin Reverses the Procoagulant Properties of Stimulated Endothelial Cells

Summary

We examined the ability of unfractionated heparin to modulate the procoagulant activities of stimulated endothelial cells (EC). Confluent human venous umbilical EC were incubated with heparin before or after stimulation, then rinsed extensively to eliminate any heparin in the solution. EC, stimulated for 4 h with endotoxin and interleukin 1β, expressed tissue factor and prothrombinase activities. When EC were treated with heparin (6 and 60 μg/ml) during the last 10 min of the stimulation period, EC-related procoagulant activities were inhibited in a dose-dependent manner (80-90% inhibition at 60 μg/ml). The inhibition was antithrombin-dependent and it disappeared after heparin removal in less than 15 min at 37° C but persisted at 4° C.

When EC were treated with heparin (60 μg/ml) for 24 h then extensively washed before stimulation, the anticoagulant effect was more modest (50% inhibition). The effect was antithrombin-dependent. Inhibition was maximum after 18-24 h of pretreatment of EC with heparin and was stable for at least 7 h. The cell surface displayed a “heparin-like” activity: treatment by heparin doubled the rate of thrombin-antithrombin complex formation and this effect was heparinase sensitive and chondroitinase ABC insensitive.

Thus, heparin modulates the procoagulant properties of stimulated EC according to two distinct mechanisms. The first one is rapid and transient, probably related to the presence of heparin molecules bound at the membrane surface. The second is delayed and persistent, and our results suggest that it is mediated by an increase in the membrane heparan sulfate molecules.

• References

• 1 Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-1121
• 2 Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Hemostasis and Thrombosis Colman RW, Hirsh J, Marder VJ, Salzman EW. eds JB Lippincott Company; Philadelphia: 1994. pp 837-860
• 3 Barzu T, Van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen JP. Endothelial bindings sites for heparin. Specificity and role in heparin neutralization. Biochem J 1986; 238: 847-854
• 4 Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-1737
• 5 Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984; 74: 341-350
• 6 Marcum JA, Rosenberg RD. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126: 365-372
• 7 Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stem K. Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest 1985; 75: 272-279
• 8 Shimada K, Ozawa T. Evidence that cell surface heparan sulfate is involved in the high affinity thrombin binding to cultured porcine aortic endothelial cells. J Clin Invest 1985; 75: 1308-1316
• 9 Nader HB, Buonassisi V, Colburn P, Dietrich CP. Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J Cell Physiol 1989; 140: 305-310
• 10 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756
• 11 Diquélou A, Dupouy D, Gaspin D, Constans J, Sié P, Boneu B, Sakariassen KS, Cadroy Y. Relationship between endothelial tissue factor and thrombo-genesis under blood flow conditions. Thromb Haemost 1995; 74: 778-783
• 12 Sié P, Lansen J, Lacheretz F, Verschuere B, Boneu B. Comparative turnover of heparin cofactor II and antithrombin III in baboons. Influence of heparin and pentosan poly sulphate administration. Thromb Haemost 1986; 56: 302-307
• 13 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
• 14 Rao LVM, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-129
• 15 Boneu B, Dol F, Caranobe C, Sié P, Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-291
• 16 Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factorpathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-3357
• 17 Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1β-and tumor necrosis factor α-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990; 144: 383-390
• 18 de Agostini A, Ramus MA, Rosenberg RD. Differential partition of anticoagulant heparan sulfate proteoglycans synthesized by endothelial and fibroblastic cell lines. J Cell Biochem 1994; 54: 174-185
• 19 Kojima T, Leone CW, Marchildon GA, Marcum JA, Rosenberg RD. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat micro vascular endothelial cells. J Biol Chem 1992; 267: 4859-4869
• 20 de Agostini A, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111: 1293-1304
• 21 Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, Cohen IR. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83: 752-756